Episode 376 -- DOJ's Unicat Settlement and the Future Look of Trade Enforcement Actions
Everything Compliance: Episode 156, To Document or Not Edition
Regulatory Ramblings: Episode 71 – Crypto Fault Lines: Stablecoins, Meme Coins & the Fight for Clarity PLUS: Sanctions, Shell Companies & Fragmented Global Trade
Compliance into the Weeds: USRA Declination Case Study - Self-Disclosure Best Practices
Episode 364 -- Five Strategies to Mitigate a New Risk Environment
Episode 358 - Ethics and Compliance Trends for 2025: Is Your Company Prepared?
U.S. Introduces “Fair and Reciprocal Plan,” Marking Significant and Impactful Shift in Trade Policy
FCPA Compliance Report: Strategic ROI - Navigating Export Controls and Compliance
FCPA Compliance Report – Episode 732 – Understanding Anti-Boycott Compliance with Alexander Cotoia
Leaders in Law: The State of International Trade with Neena Shenai
AGG Talks: Cross-Border Business Podcast - Episode 18: Navigating U.S. Sanctions and Their Implications for Non-U.S. Individuals and Entities
Navigating U.S. Sanctions and Their Implications for Non-U.S. Individuals and Entities
Episode 328 -- Sanctions Enforcement Risks and Redlines
Corruption, Crime & Compliance: Boeing Pays $51 Million for ITAR Violations
Episode 315 - Boeing Pays $51 Million for ITAR Violations
Wiley's 10 Key Trade Developments: Evolution of Export Controls
FINCast Ep. 39 – State of Russia Sanctions Two Years After the Invasion
Wiley’s Top 10 Trade Developments: Heightened Sanctions and Export Control Enforcement
Video: Making Trade Inclusive for All Americans: A Conversation with SAP's Michelle Trong Perrin-Steinberg
Corruption, Crime and Compliance: Trade Compliance Trends and Expectations with Gabrielle Griffith
Blank Rome presents a new summer webinar series where our interdisciplinary team will unpack the most pressing legal, regulatory, and policy developments from the Trump Administration’s first 180 days. Each session offers...more
On June 18, 2025, the U.S. Food and Drug Administration (“FDA”) announced an immediate review of new clinical trials that export American citizens’ biological materials to countries of concern, such as China, for genetic...more